{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:02:36Z","timestamp":1779811356657,"version":"3.53.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01214-1","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:02:33Z","timestamp":1773853353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative In Vitro-In Silico Platform for Dose\u2013Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4440","authenticated-orcid":false,"given":"Mackenzie","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2468-1164","authenticated-orcid":false,"given":"Yvonne","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5371-1231","authenticated-orcid":false,"given":"Saumya","family":"Gade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3223-2443","authenticated-orcid":false,"given":"Hannah","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4042-9779","authenticated-orcid":false,"given":"Michael","family":"Catucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7556-5298","authenticated-orcid":false,"given":"Christopher","family":"Zdyrski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7449-1661","authenticated-orcid":false,"given":"Aleksandra","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3277-5525","authenticated-orcid":false,"given":"Megan","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-0801","authenticated-orcid":false,"given":"Corey","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7943-7202","authenticated-orcid":false,"given":"Travis","family":"Laver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-6898","authenticated-orcid":false,"given":"Emily","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1013-7321","authenticated-orcid":false,"given":"Maria","family":"Orbay-Cerrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7270-3568","authenticated-orcid":false,"given":"Natalie","family":"Christianson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9368-1535","authenticated-orcid":false,"given":"Mohamed","family":"Elbadawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-2282","authenticated-orcid":false,"given":"Koichi","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-9567","authenticated-orcid":false,"given":"Andrew","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2168-5809","authenticated-orcid":false,"given":"Karin","family":"Allenspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-3111","authenticated-orcid":false,"given":"Jonathan P.","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"3","key":"1214_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021May 1;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1214_CR2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s00345-023-04428-6","volume":"41","author":"CGJI van Straten","year":"2023","unstructured":"van Straten CGJI, Bruins MH, Dijkstra S, Cornel EB, Kortleve MDH, de Vocht TF, et al. The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients. World J Urol. 2023July 1;41(7):1829\u201335.","journal-title":"World J Urol"},{"key":"1214_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154349","author":"F Claps","year":"2024","unstructured":"Claps F, Biasatti A, Di Gianfrancesco L, Ongaro L, Giannarini G, Pavan N, et al. The prognostic significance of histological subtypes in patients with muscle-invasive bladder cancer: an overview of the current literature. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13154349.","journal-title":"J Clin Med"},{"issue":"3","key":"1214_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote RJ, Groshen S, Feng AC, Boyd SD, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666\u201375.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1214_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/jnci\/djq121","volume":"102","author":"JL Gore","year":"2010","unstructured":"Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, et al. Use of Radical Cystectomy for Patients With Invasive Bladder Cancer. JNCI J Natl Cancer Inst. 2010June 2;102(11):802\u201311.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"5","key":"1214_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bju.16366","volume":"134","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Veccia A, Montanaro F, Pettenuzzo G, Franco A, Manfredi C, et al. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int. 2024Nov 1;134(5):684\u201395.","journal-title":"BJU Int"},{"key":"1214_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080749","author":"J Dobruch","year":"2021","unstructured":"Dobruch J, Oszczud\u0142owski M. Bladder cancer: current challenges and future directions. Medicina (Mex). 2021. https:\/\/doi.org\/10.3390\/medicina57080749.","journal-title":"Medicina (Mex)"},{"key":"1214_CR8","doi-asserted-by":"publisher","unstructured":"Knapp DW, Dhawan D, Ramos-Vara JA, et al. Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans. Front Oncol. 2020;9:1493. Published 2020 Jan 21. https:\/\/doi.org\/10.3389\/fonc.2019.01493. Accessed 4 Dec 2024.","DOI":"10.3389\/fonc.2019.01493"},{"issue":"3","key":"1214_CR9","first-page":"323","volume":"5","author":"I Ahmad","year":"2012","unstructured":"Ahmad I, Sansom OJ, Leung HY. Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Dis Model Mech. 2012May 1;5(3):323\u201332.","journal-title":"Dis Model Mech"},{"key":"1214_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/BLC-170145","volume":"4","author":"BC Sommer","year":"2018","unstructured":"Sommer BC, Dhawan D, Ratliff TL, Knapp DW. Naturally-occurring canine invasive urothelial carcinoma: a model for emerging therapies. Bladder Cancer. 2018;4:149\u201359.","journal-title":"Bladder Cancer"},{"issue":"1","key":"1214_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jvim.12013","volume":"27","author":"DW Knapp","year":"2013","unstructured":"Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, et al. Randomized Trial of Cisplatin versus Firocoxib versus Cisplatin\/Firocoxib in Dogs with Transitional Cell Carcinoma of the Urinary Bladder. J Vet Intern Med. 2013Jan 1;27(1):126\u201333.","journal-title":"J Vet Intern Med"},{"key":"1214_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101472","author":"MM Tsamouri","year":"2021","unstructured":"Tsamouri MM, Steele TM, Mudryj M, Kent MS, Ghosh PM. Comparative cancer cell signaling in muscle-invasive urothelial carcinoma of the bladder in dogs and humans. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9101472.","journal-title":"Biomedicines"},{"key":"1214_CR13","unstructured":"Marconato L, Nitzl DB, Melzer-Ruess KJ, Keller MA, Buchholz J. Chemotherapy and radiation therapy in 4 dogs with muscle-invasive transitional cell carcinoma of the urinary tract. Can Vet J. 2012;53(8):875\u2013879."},{"issue":"2","key":"1214_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5326\/0400131","volume":"40","author":"VJ Poirier","year":"2004","unstructured":"Poirier VJ, Forrest LJ, Adams WM, Vail DM. Piroxicam, Mitoxantrone, and Coarse Fraction Radiotherapy for the Treatment of Transitional Cell Carcinoma of the Bladder in 10 Dogs: A Pilot Study. J Am Anim Hosp Assoc. 2004Mar 1;40(2):131\u20136.","journal-title":"J Am Anim Hosp Assoc"},{"issue":"4","key":"1214_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1939-1676.2012.00946.x","volume":"26","author":"MW Nolan","year":"2012","unstructured":"Nolan MW, Kogan L, Griffin LR, Custis JT, Harmon JF, Biller BJ, et al. Intensity-Modulated and Image-Guided Radiation Therapy for Treatment of Genitourinary Carcinomas in Dogs. J Vet Intern Med. 2012July 1;26(4):987\u201395.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"1214_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1292\/jvms.19-0662","volume":"83","author":"L Malfassi","year":"2021","unstructured":"Malfassi L, Fidanzio F, Sala M, Marcarini S, Mazza G, Carrara N, et al. A combined protocol with piroxicam, chemotherapy, and whole pelvic irradiation with simultaneous boost volumetric modulated arc radiotherapy for muscle-invasive canine urinary transitional cell carcinoma: first clinical experience. J Vet Med Sci. 2021;83(4):695\u2013704.","journal-title":"J Vet Med Sci"},{"key":"1214_CR17","unstructured":"Zdyrski C, Gabriel V, Ospina O, Wickham H, Sahoo D, Dao K, et al. Establishment and Characterization of Novel Canine Organoids with Organ-Specific Physiological Similarity. 2022."},{"key":"1214_CR18","doi-asserted-by":"crossref","unstructured":"Elbadawy M, Usui T, Mori T, Tsunedomi R, Hazama S, Nabeta R, et al. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. Cancer Sci. 2019 Sept 1;110(9):2806\u201321.","DOI":"10.1111\/cas.14118"},{"issue":"1","key":"1214_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12915-023-01799-5","volume":"21","author":"K Allenspach","year":"2023","unstructured":"Allenspach K, Zavros Y, Elbadawy M, Zdyrski C, Mochel JP. Leveraging the predictive power of 3D organoids in dogs to develop new treatments for man and man\u2019s best friend. BMC Biol. 2023Dec 29;21(1):297.","journal-title":"BMC Biol"},{"issue":"1","key":"1214_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell. 2020Jan 2;26(1):17-26.e6.","journal-title":"Cell Stem Cell"},{"key":"1214_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107762","author":"CJ de Witte","year":"2020","unstructured":"de Witte CJ, Espejo Valle-Inclan J, Hami N, L\u00f5hmussaar K, Kopper O, Vreuls CPH, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses. Cell Rep. 2020. https:\/\/doi.org\/10.1016\/j.celrep.2020.107762.","journal-title":"Cell Rep"},{"issue":"1","key":"1214_CR22","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","volume":"14","author":"M Minoli","year":"2023","unstructured":"Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat Commun. 2023Apr 18;14(1):2214.","journal-title":"Nat Commun"},{"key":"1214_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112958","author":"M Berndt-Paetz","year":"2023","unstructured":"Berndt-Paetz M, Han S, Weimann A, Reinhold A, N\u00fcrnberger S, Neuhaus J. Cell line-based human bladder organoids with bladder-like self-organization\u2014a new standardized approach in bladder cancer research. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11112958.","journal-title":"Biomedicines"},{"issue":"51","key":"1214_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2024.104459","volume":"1","author":"A Reinhold","year":"2025","unstructured":"Reinhold A, Glasow A, N\u00fcrnberger S, Weimann A, Telemann L, Stolzenburg JU, et al. Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids. Photodiagnosis Photodyn Ther. 2025Feb;1(51):104459.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1214_CR25","doi-asserted-by":"crossref","unstructured":"Zerp SF, Bibi Z, Verbrugge I, Voest EE, Verheij M. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system. Clin Transl Radiat Oncol. 2020 Sept 1;24:1\u20139.","DOI":"10.1016\/j.ctro.2020.05.012"},{"key":"1214_CR26","doi-asserted-by":"crossref","unstructured":"Pasch CA, Favreau PF, Yueh AE, Babiarz CP, Gillette AA, Sharick JT, et al. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Clin Cancer Res. 2019 Sept 3;25(17):5376\u201387.","DOI":"10.1158\/1078-0432.CCR-18-3590"},{"key":"1214_CR27","doi-asserted-by":"crossref","unstructured":"Kothadiya S, Cutshaw G, Uthaman S, Hassan N, Sahoo DK, Wickham H, et al. Cisplatin-Induced Metabolic Responses Measured with Raman Spectroscopy in Cancer Cells, Spheroids, and Canine-Derived Organoids. ACS Appl Mater Interfaces. 2024 Sept 25;16(38):50267\u201381.","DOI":"10.1021\/acsami.4c08629"},{"issue":"23","key":"1214_CR28","first-page":"3881","volume":"41","author":"H von der Maase","year":"2023","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter. Phase III Study J Clin Oncol. 2023Aug 10;41(23):3881\u201390.","journal-title":"Phase III Study J Clin Oncol"},{"key":"1214_CR29","doi-asserted-by":"crossref","unstructured":"Jiang D (Maria), Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, et al. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb 1;17(1):38\u201345.","DOI":"10.1016\/j.clgc.2018.09.021"},{"issue":"1","key":"1214_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol. 2024;212(1):3\u201310.","journal-title":"J Urol"},{"key":"1214_CR31","doi-asserted-by":"crossref","unstructured":"Song YP, McWilliam A, Hoskin PJ, Choudhury A. Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nat Rev Urol. 2019 Sept 1;16(9):511\u201322.","DOI":"10.1038\/s41585-019-0199-x"},{"issue":"6","key":"1214_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrurol.2017.30","volume":"14","author":"DP Nguyen","year":"2017","unstructured":"Nguyen DP, Thalmann GN. Contemporary update on neoadjuvant therapy for bladder cancer. Nat Rev Urol. 2017June 1;14(6):348\u201358.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1214_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3233\/BLC-190235","volume":"5","author":"MD Galsky","year":"2019","unstructured":"Galsky MD, Ma E, Shah-Manek B, Mills R, Ha L, Krebsbach C, et al. Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists. Bladder Cancer. 2019Dec 4;5(4):281\u20138.","journal-title":"Bladder Cancer"},{"issue":"10","key":"1214_CR34","first-page":"1201","volume":"52","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Matsumoto H, Misumi T, Ito H, Hirata H, Nagao K, et al. The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study. Jpn J Clin Oncol. 2022Oct 1;52(10):1201\u20137.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1214_CR35","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017June 1;71(6):952\u201360.","journal-title":"Eur Urol"},{"issue":"8","key":"1214_CR36","doi-asserted-by":"publisher","first-page":"952","DOI":"10.6004\/jnccn.2013.0116","volume":"11","author":"RC Chen","year":"2013","unstructured":"Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2013Aug 1;11(8):952\u201360.","journal-title":"J Natl Compr Cancer Netw J Natl Compr Canc Netw"},{"issue":"4","key":"1214_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","volume":"19","author":"TJ Royce","year":"2021","unstructured":"Royce TJ, Liu Y, Milowsky MI, Efstathiou JA, Jani AB, Fischer-Valuck B, et al. Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2021Aug 1;19(4):362\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"1214_CR38","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017Dec 14;171(7):1678-1691.e13.","journal-title":"Cell"},{"key":"1214_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063140","author":"S Nagasawa","year":"2021","unstructured":"Nagasawa S, Takahashi J, Suzuki G, Hideya Y, Yamada K. Why concurrent CDDP and radiotherapy has synergistic antitumor effects: a review of in vitro experimental and clinical-based studies. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22063140.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1214_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1541-7786.MCR-04-0032","volume":"3","author":"HJ Boeckman","year":"2005","unstructured":"Boeckman HJ, Trego KS, Turchi JJ. Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining. Mol Cancer Res. 2005May 1;3(5):277\u201385.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"1214_CR41","first-page":"65","volume":"4","author":"W Greco","year":"1992","unstructured":"Greco W, Unkelbach HD, P\u00f6ch G, S\u00fchnel J, Kundi M, B\u00f6deker W. Consensus on concepts and terminology for combined-action assessment: the Saariselk\u00e4 agreement. Arch Complex Environ Stud. 1992;4(3):65\u20139.","journal-title":"Arch Complex Environ Stud"},{"issue":"1","key":"1214_CR42","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1038\/s41467-021-24789-z","volume":"12","author":"DJ Wooten","year":"2021","unstructured":"Wooten DJ, Meyer CT, Lubbock ALR, Quaranta V, Lopez CF. MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat Commun. 2021July 29;12(1):4607.","journal-title":"Nat Commun"},{"issue":"2","key":"1214_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","volume":"8","author":"CT Meyer","year":"2019","unstructured":"Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, et al. Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Cell Syst. 2019Feb 27;8(2):97-108.e16.","journal-title":"Cell Syst"},{"issue":"4","key":"1214_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/jvp.13433","volume":"47","author":"AP Woodward","year":"2024","unstructured":"Woodward AP. Bayesian estimation in veterinary pharmacology: A conceptual and practical introduction. J Vet Pharmacol Ther. 2024July 1;47(4):322\u201352.","journal-title":"J Vet Pharmacol Ther"},{"key":"1214_CR45","volume":"179","author":"V Gabriel","year":"2022","unstructured":"Gabriel V, Zdyrski C, Sahoo DK, Dao K, Bourgois-Mochel A, Kopper J, et al. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research. J Vis Exp. 2022Jan 31;179:e63515.","journal-title":"J Vis Exp"},{"key":"1214_CR46","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1535-7163.MCT-04-0331","volume":"15;6(3)","author":"T Frgala","year":"2007","unstructured":"Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther. 2007;15;6(3):886\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1214_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jml.2012.11.001","volume":"68","author":"DJ Barr","year":"2013","unstructured":"Barr DJ, Levy R, Scheepers C, Tily HJ. Random effects structure for confirmatory hypothesis testing: keep it maximal. J Mem Lang. 2013;68(3):255\u201378.","journal-title":"J Mem Lang"},{"key":"1214_CR48","unstructured":"Betancourt M. (What\u2019s the Probabilistic Story) Modeling Glory? [Internet]. 2021. Available from: https:\/\/github.com\/betanalpha\/knitr_case_studies\/tree\/master\/generative_modeling.\u00a0Commit99e07946e73d4c45ea757c4cde7882495e6519a8"},{"issue":"3\u20134","key":"1214_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1471082X18759140","volume":"18","author":"N Umlauf","year":"2018","unstructured":"Umlauf N, Kneib T. A primer on Bayesian distributional regression. Stat Model. 2018;18(3\u20134):219\u201347.","journal-title":"Stat Model"},{"key":"1214_CR50","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/oik.05985","volume":"1;128(7)","author":"NP Lemoine","year":"2019","unstructured":"Lemoine NP. Moving beyond noninformative priors: why and how to choose weakly informative priors in Bayesian analyses. Oikos. 2019;1;128(7):912\u201328.","journal-title":"Oikos"},{"issue":"1","key":"1214_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v076.i01","volume":"76","author":"B Carpenter","year":"2017","unstructured":"Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A Probabilistic Programming Language. J Stat Softw. 2017Jan 11;76(1):1\u201332.","journal-title":"J Stat Softw"},{"key":"1214_CR52","unstructured":"R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: https:\/\/www.R-project.org. Accessed 2 Apr 2025."},{"key":"1214_CR53","doi-asserted-by":"crossref","unstructured":"Vehtari A, Gelman A, Simpson D, Carpenter B, B\u00fcrkner PC. Rank-normalization, folding, and localization: An improved\u00a0$$\\widehat{R}$$ for assessing convergence of MCMC. Bayesian Anal [Internet]. 2021 June 1 [cited 2024 Dec 10];16(2). Available from: http:\/\/arxiv.org\/abs\/1903.08008","DOI":"10.1214\/20-BA1221"},{"key":"1214_CR54","unstructured":"Betancourt M. Diagnosing biased inference with divergences [Internet]. 2017. Available from: https:\/\/github.com\/betanalpha\/knitr_case_studies\/tree\/master\/divergences_and_bias, commit b474ec1a5a79347f7c9634376c866fe3294d657a"},{"key":"1214_CR55","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis [Internet]. New York: Springer-Verlag; 2016. Available from: https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4_9"},{"issue":"1","key":"1214_CR56","first-page":"414","volume":"30","author":"M Kay","year":"2024","unstructured":"Kay M. ggdist: Visualizations of Distributions and Uncertainty in the Grammar of Graphics. IEEE Trans Vis Comput Graph. 2024Jan;30(1):414\u201324.","journal-title":"IEEE Trans Vis Comput Graph"},{"key":"1214_CR57","unstructured":"Melamed MR, Wolinska WH. On the significance of intracytoplasmic inclusions in the urinary sediment. Am J Pathol. Am J Pathol 38(6)."},{"issue":"215","key":"1214_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","volume":"1","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: State of the art and future perspectives. Adv Drug Deliv Rev. 2024Dec;1(215):115421.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1214_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.synres.2018.04.001","volume":"7","author":"TC Chou","year":"2018","unstructured":"Chou TC. The combination index (CI\u202f<\u202f1) as the definition of synergism and of synergy claims. Synergy. 2018;7(1):49\u201350.","journal-title":"Synergy"},{"key":"1214_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/srep25523","volume":"10;6(1)","author":"NR Twarog","year":"2016","unstructured":"Twarog NR, Stewart E, Hammill CV, Shelat AA. BRAID: a unifying paradigm for the analysis of combined drug action. Sci Rep. 2016;10;6(1):25523.","journal-title":"Sci Rep"},{"key":"1214_CR61","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-14-3763","volume":"31;75(11)","author":"JC Ashton","year":"2015","unstructured":"Ashton JC. Drug combination studies and their synergy quantification using the Chou\u2013Talalay method\u2014letter. Cancer Res. 2015;31;75(11):2400\u20132400.","journal-title":"Cancer Res"},{"issue":"12","key":"1214_CR62","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1111\/cas.13418","volume":"108","author":"T Usui","year":"2017","unstructured":"Usui T, Sakurai M, Nishikawa S, Umata K, Nemoto Y, Haraguchi T, et al. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells. Cancer Sci. 2017Dec 1;108(12):2383\u201392.","journal-title":"Cancer Sci"},{"issue":"3","key":"1214_CR63","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/psp4.12588","volume":"10","author":"C Maier","year":"2021","unstructured":"Maier C, Hartung N, Kloft C, Huisinga W, de Wiljes J. Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology. CPT Pharmacomet Syst Pharmacol. 2021Mar 1;10(3):241\u201354.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"1214_CR64","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.stemcr.2023.05.009","volume":"18","author":"KB Jensen","year":"2023","unstructured":"Jensen KB, Little MH. Organoids are not organs: Sources of variation and misinformation in organoid biology. Stem Cell Rep. 2023June 13;18(6):1255\u201370.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"1214_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-020-02649-x","volume":"70","author":"R Cao","year":"2021","unstructured":"Cao R, Yuan L, Ma B, Wang G, Tian Y. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother. 2021Jan 1;70(1):1\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1214_CR66","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41746-025-01560-y","volume":"8","author":"Z Bai","year":"2025","unstructured":"Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson IM, et al. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digit Med. 2025Mar 22;8(1):174.","journal-title":"Npj Digit Med"},{"key":"1214_CR67","doi-asserted-by":"publisher","unstructured":"Elbadawy M, Zdyrski C, Wickham H, Saba C, Thenuwara S, Mosichuk A, Sahoo D, Mochel J, Allenspach K. Experimental methods for establishing and maintaining canine bladder cancer organoids. 2025. https:\/\/doi.org\/10.1201\/9781003449942-61.","DOI":"10.1201\/9781003449942-61"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01214-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:03:48Z","timestamp":1779807828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01214-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01214-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This submission represents original unpublished work. K. Allenspach is a co-founder of LifEngine Animal Health and 3D Health Solutions. She serves as a consultant for Ceva Animal Health, LifeDiagnostics, Antech Diagnostics, Boehringer Ingelheim, Purina, hills, and Mars. J.P. Mochel is a co-founder of LifEngine Animal Health (LEAH) and 3D Health Solutions. Dr. Mochel is a consultant for Ceva Animal Health, Ethos Animal Health, Dechra ltd, and LifEngine Animal Health. C. Zdyrski is the Director of Research and Product Development at 3D Health Solutions. Other authors do not have any competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"ChatGPT-5 (OpenAI, 2025) was used to improve the grammar of this manuscript. Its use was limited to enhancing readability, without altering the scientific content or interpretations. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Assistive AI in Scientific Writing"}}],"article-number":"74"}}